IMMUNOSUPPRESSIVE DRUG THERAPY IN LUPUS GLOMERULONEPHRITIS

肾脏疾病的最佳治疗 与系统性红斑狼疮相关的疾病是有争议的 的 强化的、间歇性的免疫抑制药物治疗的疗效正在被 在活动性狼疮性肾小球肾炎患者中进行评估。 的比较 是在间歇性皮质类固醇脉冲剂量之间进行的， 环磷酰胺，以及短和长脉冲之间的过程 环磷酰胺 肾活检记录为活动性的患者 肾小球肾炎患者接受泼尼松治疗，并随机接受 伴随（a）静脉冲击甲基强的松龙，每月6次 （B）每月静脉内脉冲环磷酰胺，持续6个月，或 (c)环磷酰胺每月脉冲6个月，随后维持 环磷酰胺脉冲治疗方案，每3个月一次，持续两个月 年 迄今为止的结果表明， 接受以下治疗的患者发生进行性肾功能不全的概率 脉冲甲基强的松龙比脉冲治疗的患者 环磷酰胺

The optimal treatment of the proliferative forms of kidney disease associated with systemic lupus erythematosus is controversial. The efficacy of intensive, intermittent immunosuppressive drug therapy is being evaluated in patients with active lupus glomerulonephritis. A comparison is being made between intermittent pulse doses of corticosteroid and cyclophosphamide, as well as between a short and long course of pulse cyclophosphamide. Patients with renal biopsy documented active glomerulonephritis were treated with prednisone and randomized to receive concomitantly (a) intravenous pulse methylprednisolone monthly for 6 months, or (b) intravenous pulse cyclophosphamide monthly for 6 months, or (c) pulse cyclophosphamide monthly for 6 months followed by a maintenance regimen of pulse cyclophosphamide every 3 months for an additional two years. Results to date indicate a statistically significant, higher probability of progressive renal insufficiency in patients treated with pulse methylprednisolone than in patients treated with pulse cyclophosphamide.